Development of an effective malaria vaccine that could be deployed widely in endemic
areas has proved to be more difficult than was anticipated, when the first clinical trials of …

Background Falciparum malaria remains a global health problem. Two vaccines, based on
the circumsporozoite antigen, are available. RTS, S/AS01 was recommended for use in …

Background Adding malaria vaccination to existing interventions could help to reduce the
health burden due to malaria. This study modelled the potential public health impact of the …

Aim The review summarizes the recent empirical evidence on the efficacy, safety, and
community perception of malaria vaccines in Africa. Methods Academic Search Complete …

Malaria affects millions of lives annually, particularly in tropical and subtropical regions.
Despite being largely preventable, 2021 witnessed 247 million infections and over 600,000 …

Prior to progression to Clinical Development Phase III, GlaxoSmithKline Biologicals
performed a pooled analysis of phase two safety data following administration of 8860 …

There is hope that 2023 could bring regulatory approval, licensing, and implementation
programs for safe and effective adjuvanted vaccines to prevent malaria. Clinical trials …

Background The RTS, S/AS malaria vaccine is being developed for delivery through the
World Health Organization's Expanded Program on Immunization (EPI). We assessed the …

Malaria was estimated to result in 214 million clinical cases and 438,000 deaths in 2015,
primarily in children under 5 years of age. In Africa, malaria causes approximately 10% of all …

The RTS, S vaccine has recently been recommended for implementation as a childhood
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …